All articles tagged with #lsd
Scientists at UCSF are exploring a pharmaceutical form of LSD, MM120, as a potential treatment for generalized anxiety disorder (GAD), showing promising results in reducing symptoms by promoting neuroplasticity and brain communication, with manageable side effects, offering hope for those unresponsive to traditional medications.
UCSF is exploring a novel psychedelic drug, MM120, derived from LSD, which has shown promising results in reducing symptoms of generalized anxiety disorder by promoting neuroplasticity and improving brain communication, potentially offering a more effective treatment than current medications, despite some mild side effects.
A recent clinical trial suggests that a single higher dose of LSD (100 micrograms) may significantly reduce anxiety symptoms for at least three months in some patients, with minimal side effects, highlighting its potential as a treatment option for anxiety disorders, especially for those unresponsive to traditional medications.
A new study shows that a single high dose of LSD (MM120) can significantly reduce anxiety and depression in adults with generalized anxiety disorder, with effects lasting up to 12 weeks, though environmental factors may also influence outcomes. The research supports the potential of psychedelics as future psychiatric treatments, pending further studies and FDA approval.
Research suggests that a single dose of MM120, an LSD formulation, may significantly reduce symptoms of generalized anxiety disorder with effects lasting up to three months, though further studies are needed to confirm safety and efficacy.
Scientists at UC Davis developed JRT, a modified LSD compound that promotes brain cell growth and repair without causing hallucinations, showing promise for treating brain disorders like schizophrenia and depression in animal studies.
A Canadian study published in JAMA Psychiatry found that individuals who visit the ER for psychedelic use, such as LSD and ecstasy, have a 3.5-fold increased risk of developing schizophrenia compared to the general population. The study tracked over 9.2 million people in Ontario and noted that 4% of those with hallucinogen-related ER visits were diagnosed with schizophrenia within three years. While the study highlights a significant association, it does not establish a causal link, and researchers caution against psychedelic use, especially for those with a predisposition to psychosis.
The FDA has granted breakthrough therapy status to an LSD formulation, MM120, for treating generalized anxiety disorder, with promising results from a Phase 2 trial showing significant symptom improvement and remission in patients. This designation is expected to bring in a substantial investment for further development, and MindMed plans to begin Phase 3 trials later this year.
A new study conducted by biopharmaceutical company MindMed has found that a single dose of MM120, a form of LSD, can provide lasting relief to patients suffering from generalized anxiety disorder (GAD), with a 48% rate of remission after 12 weeks and about 65% of patients seeing improvements within three months. The drug will need to go through the standard FDA approval process and will soon enter phase III trials.
A single dose of a new LSD formulation, MM120, has shown promising results in treating generalized anxiety disorder, leading to a 48% remission rate and significant improvement for 65% of patients within three months. The drug has received breakthrough therapy status from the FDA, and the biopharmaceutical company, Mind Medicine Inc., is developing it. The study's results also indicate potential benefits for depression symptoms. This marks the first time LSD has been studied in a medical setting in over 40 years, and the breakthrough designation will facilitate the drug's development process.
A study found that even small doses of LSD, specifically 26 micrograms, increased brain complexity by about 12 percent without altering consciousness, suggesting potential therapeutic benefits for mental health and task performance. The research indicates that microdoses of LSD affect the brain similarly to higher doses, potentially explaining reports of increased creativity and social connection. However, clinical trials have not yet proven overall benefits of microdosing LSD, and further research is needed to assess whether the observed increase in brain complexity results in cognitive, behavioral, or therapeutic outcomes.
Margaret Mead, a renowned 20th-century scientist, became involved in early LSD experiments in the 1950s, considering psychedelics as a potential catalyst for cultural evolution. Her interest in LSD and its potential impact on society led her to contemplate taking the drug herself, but ultimately, she decided against it due to concerns about maintaining control and the potential risks to her personal life and career. Her involvement in psychedelic research sheds light on a lesser-known aspect of her legacy and the potential impact she could have had on the history of drugs in the 20th century.
New research suggests that low doses of MDMA, also known as ecstasy, may help reduce the challenging effects associated with psychedelic drugs like LSD and psilocybin. The study found that co-using a low dose of MDMA with psilocybin or LSD resulted in significantly lower levels of negative experiences such as grief and fear, while also increasing positive experiences like self-compassion, love, and gratitude. However, the study has limitations, including a small sample size and reliance on self-reported data, and further research is needed to determine the safety and potential benefits of combining MDMA with psilocybin or LSD.
A study from the University of Chicago suggests that low doses of LSD may have potential antidepressant effects in individuals with mild to moderate depressive symptoms. The study involved 39 healthy volunteers and found that participants with higher depression scores experienced significant increases in positive mood measures following LSD consumption, and reported a notable decrease in depression scores 48 hours after the LSD session. However, the study is limited by its small sample size and the need for further research to replicate and extend the findings to other samples.
A study published in the journal Substance Use & Misuse reveals a significant increase in LSD use among business managers in the United States. The research, aimed at understanding evolving patterns of substance use, found that LSD use within the past year has been steadily rising among full-time employees, with an even more pronounced increase among business managers. The study suggests that the growing interest in psychedelics like LSD, fueled by anecdotal reports and notable figures like Steve Jobs and Bill Gates, may be influencing the behavior of business leaders. The study also found that changing perceptions of LSD's risks did not explain the trend, indicating that perceptions of the potential positive effects of LSD use may be driving this temporal trend among business managers. However, the study does not delve into the underlying motivations behind this increase in LSD use among business managers.